Biosimilar CT-P43 Matches Ustekinumab in Treating Moderate to Severe Plaque Psoriasis

Why It Matters

Demonstrating biosimilar parity with ustekinumab expands affordable biologic access and supports payer adoption, potentially lowering treatment costs for a high‑burden chronic disease.

Key Takeaways

• CT‑P43 met primary PASI75 equivalence at week 12.
• Week‑52 PASI responses matched reference ustekinumab.
• Safety and adverse events comparable between biosimilar and reference.
• Antidrug antibody rates similar; no new immunogenicity signals.
• Switching from ustekinumab to CT‑P43 preserved efficacy.

Pulse Analysis

Biologic therapies targeting the IL‑12/23 pathway have transformed plaque psoriasis management, yet their high price tags limit patient access. Biosimilars like CT‑P43 aim to bridge this gap by offering comparable clinical outcomes at reduced cost. The recent phase‑3 trial adds robust evidence that the biosimilar not only meets regulatory equivalence criteria but also sustains long‑term skin clearance, reinforcing confidence among dermatologists and health‑system decision‑makers.

The study’s primary endpoint—PASI75 at week 12—fell within the predefined equivalence margin, and week‑52 data demonstrated near‑identical PASI50, PASI75, and PASI90 response rates between CT‑P43 and the reference product. Safety signals remained aligned, with treatment‑emergent adverse events mirroring the established profile of ustekinumab. Immunogenicity analysis showed comparable antidrug‑antibody formation, indicating the biosimilar does not introduce additional immune risks. Moreover, a planned switch cohort maintained efficacy, confirming practical interchangeability in real‑world settings.

From a market perspective, these findings could accelerate biosimilar uptake, prompting insurers to favor lower‑cost alternatives and encouraging clinicians to consider switching stable patients without compromising outcomes. As biosimilar adoption grows, the competitive pressure may drive down overall biologic spend, expanding treatment access for the estimated 125 million psoriasis patients worldwide. Regulators will likely reference this trial when evaluating future biosimilar submissions, reinforcing a pathway toward broader, more affordable biologic therapy ecosystems.